Norikazu Masuda

55PUBLICATIONS
135CO-AUTHORS
Environmental epidemiologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer cell biologyCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (55)

|Jul 08, 2026
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.

|Jun 10, 2026
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer.

|May 13, 2026
Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10).

|Apr 16, 2026
Dynamic changes in serum HER2-peptide-specific autoantibodies predict response to neoadjuvant therapy in HER2-positive breast cancer.

|Mar 19, 2026
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.

Norikazu Masuda, Hiroyuki Yasojima, Hiroko Bando

|Feb 11, 2026
Real-world outcomes of palbociclib plus endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer in Japan: a subgroup analysis of the P-BRIDGE study by age group.

Hiroko Masuda, Shigenori E Nagai, Masaya Hattori

Pageof 10

Frequent Collaborators

11 joint publications

Masakazu Toi

8 joint publications

Shigehira Saji

7 joint publications

Satoshi Morita

6 joint publications

Toshimi Takano